Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression.
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
28 02 2023
28 02 2023
Historique:
received:
26
10
2022
accepted:
01
01
2023
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer's disease (AD). In this work, a temporal lobe composite (Eτ) volume of interest (VOI) was evaluated in a longitudinal flortaucipir cohort and compared to a previously described global neocortical VOI. In a separate autopsy-confirmed study, the sensitivity of the Eτ VOI for identifying intermediate (B2) neurofibrillary tangle (NFT) pathology was evaluated. A total of 427 subjects received flortaucipir, florbetapir, MRI, and cognitive evaluation at baseline and 18 months. In a separate autopsy study, 67 subjects received ante-mortem flortaucipir scans, and neuropathological findings were recorded according to NIA-AA recommendations by two experts. Two VOIs: Eτ comprising FreeSurfer volumes (bilateral entorhinal cortex, fusiform, parahippocampal, and inferior temporal gyri) transformed to MNI space and a previously published global AD signature-weighted neocortical VOI (AD Sixty-four out of 390 analyzable subjects were identified as Eτ+/AD The Eτ VOI identified subjects with elevated temporal but not global tau (Eτ+/AD
Sections du résumé
BACKGROUND
There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer's disease (AD). In this work, a temporal lobe composite (Eτ) volume of interest (VOI) was evaluated in a longitudinal flortaucipir cohort and compared to a previously described global neocortical VOI. In a separate autopsy-confirmed study, the sensitivity of the Eτ VOI for identifying intermediate (B2) neurofibrillary tangle (NFT) pathology was evaluated.
METHODS
A total of 427 subjects received flortaucipir, florbetapir, MRI, and cognitive evaluation at baseline and 18 months. In a separate autopsy study, 67 subjects received ante-mortem flortaucipir scans, and neuropathological findings were recorded according to NIA-AA recommendations by two experts. Two VOIs: Eτ comprising FreeSurfer volumes (bilateral entorhinal cortex, fusiform, parahippocampal, and inferior temporal gyri) transformed to MNI space and a previously published global AD signature-weighted neocortical VOI (AD
RESULTS
Sixty-four out of 390 analyzable subjects were identified as Eτ+/AD
CONCLUSION
The Eτ VOI identified subjects with elevated temporal but not global tau (Eτ+/AD
Identifiants
pubmed: 36855201
doi: 10.1186/s13195-023-01160-6
pii: 10.1186/s13195-023-01160-6
pmc: PMC9972744
doi:
Substances chimiques
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Apolipoprotein E4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Informations de copyright
© 2023. The Author(s).
Références
Alzheimers Dement. 2015 Aug;11(8):964-74
pubmed: 25824567
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
Brain. 2018 May 1;141(5):1517-1528
pubmed: 29538647
J Nucl Med. 2018 Jun;59(6):937-943
pubmed: 29284675
JAMA Neurol. 2020 Jul 1;77(7):829-839
pubmed: 32338734
Acta Neuropathol. 2014 May;127(5):685-98
pubmed: 24531886
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Acta Neuropathol. 2017 Oct;134(4):619-628
pubmed: 28612291
JAMA Neurol. 2019 Mar 1;76(3):310-317
pubmed: 30508025
JAMA Neurol. 2017 Dec 1;74(12):1455-1463
pubmed: 28973551
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
JAMA. 2018 Sep 18;320(11):1151-1162
pubmed: 30326496
Neurology. 1998 Oct;51(4):993-9
pubmed: 9781519
Ann Neurol. 1999 Mar;45(3):358-68
pubmed: 10072051
JAMA Neurol. 2019 Aug 01;76(8):915-924
pubmed: 31157827
J Nucl Med. 2020 Jun;61(6):911-919
pubmed: 31712323
Neurology. 1997 Sep;49(3):786-94
pubmed: 9305341
Alzheimers Dement. 2013 Nov;9(6):666-76
pubmed: 23411393
Hum Brain Mapp. 2019 Feb 1;40(2):638-651
pubmed: 30368979
Alzheimers Dement. 2020 Mar;16(3):561-571
pubmed: 31784374
Brain. 2019 Jun 1;142(6):1723-1735
pubmed: 31009046
Cereb Cortex. 1994 Mar-Apr;4(2):138-50
pubmed: 8038565
Alzheimers Dement (Amst). 2018 Feb 14;10:221-231
pubmed: 29780867
Neuroimage. 2017 Nov 1;161:171-178
pubmed: 28756238
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2
pubmed: 9330978
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
pubmed: 7566337
Eur J Nucl Med Mol Imaging. 2017 May;44(5):825-837
pubmed: 28064343
J Neurosci. 2016 Jul 13;36(28):7364-74
pubmed: 27413148
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
J Nucl Med. 2015 Nov;56(11):1736-41
pubmed: 26338898
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Am J Pathol. 2010 Oct;177(4):1977-88
pubmed: 20802182
J Nucl Med. 2016 Oct;57(10):1599-1606
pubmed: 27230925
J Alzheimers Dis. 2012;31 Suppl 3:S189-201
pubmed: 22785390
J Neuropathol Exp Neurol. 2003 Nov;62(11):1087-95
pubmed: 14656067
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
JAMA Neurol. 2015 Mar;72(3):287-94
pubmed: 25622185
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Neurobiol Aging. 2018 Dec;72:177-185
pubmed: 30292840
Neuroimage. 2017 Aug 15;157:448-463
pubmed: 28587897
J Nucl Med. 2018 Jun;59(6):944-951
pubmed: 29191858